Adalimumab treatment of resistant chondrocalcinosis.

Humans Adalimumab / therapeutic use Chondrocalcinosis / drug therapy Female Drug Resistance Antirheumatic Agents / therapeutic use
Adalimumab Calcium pyrophosphate Chondrocalcinosis Condrocalcinosis Factor de necrosis tumoral alfa Pirofosfato cálcico Tumor necrosis factor-alpha

Journal

Reumatologia clinica
ISSN: 2173-5743
Titre abrégé: Reumatol Clin (Engl Ed)
Pays: Spain
ID NLM: 101717526

Informations de publication

Date de publication:
Oct 2024
Historique:
received: 02 05 2024
accepted: 21 06 2024
medline: 13 10 2024
pubmed: 13 10 2024
entrez: 13 10 2024
Statut: ppublish

Résumé

In this article, we present a case of resistant chondrocalcinosis who had a good response with 40mg subcutaneous adalimumab. To our knowledge, this is the first report using adalimumab successfully in severe CPDD. Anti-TNF therapy can be a good therapeutic option for second line therapy in CPPD.

Identifiants

DOI: 10.1016/j.reumae.2024.09.007 PMID: 39396355
pubmed: 39396355
pii: S2173-5743(24)00116-3
doi: 10.1016/j.reumae.2024.09.007
pii:
doi:

Substances chimiques

Adalimumab FYS6T7F842
Antirheumatic Agents 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

452-453

Informations de copyright

Copyright © 2024 Sociedad Española de Reumatología (SER), Colegio Mexicano de Reumatología (CMR) and Elsevier España, S.L.U. All rights reserved.

Auteurs

Fatih Tastekin (F)

Ege University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey. Electronic address: fatihtastekin@gmail.com.

Kenan Aksu (K)

Ege University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Adalimumab treatment of resistant chondrocalcinosis.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Adalimumab › Adalimumab treatment of resistant chondrocalcinosis.
questionsmedicales.fr › Maladies ostéomusculaires › Maladies articulaires › Arthropathies à cristaux › Chondrocalcinose › Adalimumab treatment of resistant chondrocalcinosis.
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Adalimumab treatment of resistant chondrocalcinosis.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antirhumatismaux › Adalimumab treatment of resistant chondrocalcinosis.